Please login to the form below

Not currently logged in
Email:
Password:

first-line bladder cancer

This page shows the latest first-line bladder cancer news and features for those working in and with pharma, biotech and healthcare.

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail

However, the continued approval of Imfinzi in this indication was dependent on the results from the phase 3 DANUBE trial in the first-line metastatic bladder cancer setting. ... Roche’s Tecentriq (atezolizumab) was also the first checkpoint inhibitor

Latest news

More from news
Approximately 0 fully matching, plus 13 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....